{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T23:58:58Z","timestamp":1788134338714,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A2C4001842"],"award-info":[{"award-number":["2020R1A2C4001842"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A causal relationship of bisphosphonate (BP) exposure with osteonecrosis of the jaw (ONJ) has been reported; however, a definite dose-dependent risk remains to be elucidated beyond current vague recommendations of 4-year oral BP for ONJ risk increase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify the effect of bisphosphonate cumulative dose on ONJ development in women with osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study was designed using the National Health Insurance Service\u2014National Health Screening database of Korea. Females over the age of 50 were diagnosed with osteoporosis based on the International Classification of Diseases 10th revision (ICD-10) codes (M80, M81, and M82) with bisphosphonate prescriptions. The cumulative dose of bisphosphonate was calculated using defined daily doses (DDD) to provide an accurate BP cumulative effect on ONJ occurrence. Osteonecrosis of the jaw was identified using both ICD-10 codes and related procedure codes. The incidence rates of ONJ and hazard ratios were estimated according to the bisphosphonate cumulative dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 74,491 included subjects, 190 cases of ONJ were identified. The incidence rate substantially increased after BP cumulative dose over 1 year (25.75 for DDD &amp;lt; 365, which increased to 53.43 for 365 \u2264 DDD &amp;lt; 730). Compared to subjects with a cumulative dose of DDD &amp;lt; 365, subjects with a cumulative dose of 365 \u2264 DDD &amp;lt; 730 had 2.36-fold hazard for developing ONJ (p &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A bisphosphonate cumulative dose of more than 1 year had an increased risk of ONJ development. A gradual, but not sudden, dose-dependent increase in ONJ risk with BP exposure needs to be considered in providing the optimal BP treatment duration.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.774820","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:40:35Z","timestamp":1639028435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jung-Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jeong","family":"Kwoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ryun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Suh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An Overview and Management of Osteoporosis","volume":"4","author":"S\u00f6zen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","article-title":"Drug Holidays From Bisphosphonates and Denosumab in Postmenopausal Osteoporosis: EMAS Position Statement","volume":"101","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/281812","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw Mimicking Bone Metastasis","volume":"2014","author":"Bhatt","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"B5","first-page":"1012","article-title":"Bone Scan Manifestations of Osteonecrosis of the Jaw (ONJ) in Cancer Patients: Three Unique Clinical Presentations","volume":"53","author":"Joshi","year":"2012","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31827082f0","article-title":"Role of Nuclear Medicine Imaging in Recognizing Different Causes of Osteonecrosis of the Jaw","volume":"38","author":"Joshi","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis","volume":"16","author":"Watts","year":"2010","journal-title":"Endocrine Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2013.05.013","article-title":"Diagnosis and Management of Osteoporosis in Postmenopausal Women and Older Men in the UK: National Osteoporosis Guideline Group (NOGG) Update 2013","volume":"75","author":"Compston","year":"2013","journal-title":"Maturitas"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/odi.12632","article-title":"Time to Onset of Bisphosphonate-Related Osteonecrosis of the Jaws: A Multicentre Retrospective Cohort Study","volume":"23","author":"Fung","year":"2017","journal-title":"Oral Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw\u20132014 Update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/0022034515587862","article-title":"A Large National Cohort Study of the Association Between Bisphosphonates and Osteonecrosis of the Jaw in Patients With Osteoporosis: A Nested Case-Control Study","volume":"94","author":"Kwon","year":"2015","journal-title":"J Dental Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00796","article-title":"Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients","volume":"9","author":"Jung","year":"2018","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0022034510397196","article-title":"Risk Factors for Osteonecrosis of the Jaws: A Case-Control Study From the CONDOR Dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J Dent Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4119","article-title":"The Risk of Osteonecrosis of the Jaws in Taiwanese Osteoporotic Patients Treated With Oral Alendronate or Raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2015.22.4.151","article-title":"Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons","volume":"22","author":"Kim","year":"2015","journal-title":"J Bone Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive Agent-Related Osteonecrosis of the Jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10354-016-0437-2","article-title":"[Position Paper on Medication-Related Osteonecrosis of the Jaw (MRONJ)]","volume":"166","author":"Svejda","year":"2016","journal-title":"Wien Med Wochenschr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.23191","article-title":"Review and Update on Drugs Related to the Development of Osteonecrosis of the Jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3017","article-title":"Uncertainty of Current Algorithm for Bisphosphonate-Related Osteonecrosis of the Jaw in Population-Based Studies: A Systematic Review","volume":"32","author":"Kim","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2011.02.093","article-title":"Oral Bisphosphonate Use Increases the Risk for Inflammatory Jaw Disease: A Cohort Study","volume":"70","author":"Vestergaard","year":"2012","journal-title":"J Oral Maxillofacial Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016640","article-title":"Cohort Profile: The National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea","volume":"7","author":"Seong","year":"2017","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0236665","DOI":"10.1371\/journal.pone.0236665","article-title":"Association Between Disability and Cardiovascular Event and Mortality: A Nationwide Representative Longitudinal Study in Korea","volume":"15","author":"Son","year":"2020","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40902-019-0210-8","article-title":"Pharmacoepidemiology and Clinical Characteristics of Medication-Related Osteonecrosis of the Jaw","volume":"41","author":"Son","year":"2019","journal-title":"Maxillofac Plast Reconstr Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00198-012-2013-y","article-title":"Assessing the Risk of Osteonecrosis of the Jaw Due to Bisphosphonate Therapy in the Secondary Prevention of Osteoporotic Fractures","volume":"24","author":"Lapi","year":"2013","journal-title":"Osteoporos Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2624-6","article-title":"Incidence and Risk of Osteonecrosis of the Jaw Among the Taiwan Osteoporosis Population","volume":"25","author":"Lin","year":"2014","journal-title":"Osteoporos Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/pds.3786","article-title":"Evaluation of an ICD-10 Algorithm to Detect Osteonecrosis of the Jaw Among Cancer Patients in the Danish National Registry of Patients","volume":"24","author":"Ehrenstein","year":"2015","journal-title":"Parmacoepidemiol Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e025600","DOI":"10.1136\/bmjopen-2018-02560","article-title":"Database Analysis of the Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Hungarian Patients","volume":"9","author":"Veszelyn\u00e9 Kot\u00e1n","year":"2019","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3292","article-title":"Incidence of Osteonecrosis of the Jaw Among Users of Bisphosphonates With Selected Cancers or Osteoporosis","volume":"21","author":"Tennis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.774820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:40:40Z","timestamp":1639028440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.774820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":30,"alternative-id":["10.3389\/fendo.2021.774820"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.774820","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]},"article-number":"774820"}}